Authors
Latest:
RECORD-3 Study Identifies Poor-Risk Patients With mRCCJames J. Hsieh, MD, discusses differential overall survival (OS) results of the RECORD-3 study based on 3 distinct mRCC molecular subgroups, classified by patients who harbored <em>BAP1</em> and/or <em>PBRM1</em> mutations.
Latest:
Molecular Profiling to Inform Treatment Decisions for Patients With NSCLCGiorgio Vittorio Scagliotti, MD, PhD, chief of the Medical Oncology Division at the S. Luigi Hospital, Orbassano (Torino), and head of the Department of Oncology at University of Torino, Italy, discusses the utilization of molecular profiling to inform treatment decisions for patients with non-small cell lung cancer.
Latest:
Lung Cancer Treatment-Related ToxicitiesGiorgio V. Scagliotti, MD, PhD, discusses toxicities related to chemotherapy and surgery in patients with lung cancer.
Latest:
Dr. Giselle Carnaby on Cognitive Behavioral Strategies Post-Surgery in Head and Neck CancerCarnaby says prophylactic gastrostomy tube placement may not be as supportive as previously thought in the health of the muscles in these patients.
Latest:
Nivolumab Reduces Transformation of Precancerous Leukoplakia to Oral CancerGlenn J. Hanna, MD, discusses the results of a study investigating nivolumab as treatment for proliferative leukoplakia leading to oral cancer.
Latest:
Dr. Gordon B. Mills on Moving Toward Patient-Specific Treatment in Breast Cancer​Gordon B. Mills, MD, PhD, says individualized treatment, as opposed to treating patients solely based on their malignancy type, must happen in order to improve patient outcome.
Latest:
Dr. Gordon J. Freeman on Toxicities Associated With ImmunotherapiesFreeman says when a patient is given chemotherapy, oncologists can anticipate certain toxicities and treat accordingly. With immunotherapies, Freeman says the toxicities are associated with immune attacks where there shouldn't be any. These attacks can result in side effects such as skin rashes, colitis, and neumonitis.
Latest:
The Revival of Vaccines in Lung CancerThis article provides a short historical overview of major lung cancer vaccination studies performed in the last decade to set the perspective on the development of current clinical trials of therapeutic cancer vaccines for patients with non–small cell lung cancer.
Latest:
Breast Cancer Prevention in Low and Middle Income CountriesGraham Colditz, MD, DrPH, associate director, Prevention and Control, Alvin J. Siteman Cancer Center, discusses the need to focus on breast cancer prevention in low and middle income countries.
Latest:
Lenalidomide as a Highly-Effective Maintenance Therapy in MyelomaGraham Jackson, MD, PhD, Northern Institute for Cancer Research, Newcastle University, discusses results of a study that determined lenalidomide (Revlimid) is a highly-effective maintenance therapy in myeloma patients of all ages.
Latest:
Advantages and Limitations of Nipple-Sparing MastectomyGrant W. Carlson, MD, professor of surgery, Emory University School of Medicine, chief, Division of Plastic Surgery, Emory University Hospital, discusses the advantages and limitations of nipple-sparing mastectomy.
Latest:
Evolving Paradigms in STS: Perspectives With Shreyaskumar R. Patel and Jonathan C. Trent, MDShreyaskumar R. Patel, MD and Jonathan C. Trent, MD discussed the use of trabectedin and the future of the treatment paradigms in soft tissue sarcoma.
Latest:
Targeting Cancer Stem Cells in the BRIGHTER Trial: A Q&A With Manish A. Shah, MDManish A. Shah, MD, a prominent researcher in the gastrointestinal cancer field who is helping to lead the BRIGHTER trial, discussed the ongoing research in an interview with Targeted Oncology.
Latest:
Combining Immunotherapies With Targeted Therapies and Other ImmunotherapiesGregory A. Daniels, MD, PhD, discusses opportunities to combine immunotherapies with both targeted therapies and other immunotherapies.
Latest:
Yield of Multiplex Panel Testing Compared With Expert Opinion and Validation Prediction ModelsGregory E. Idos, MD, discusses a study examining the yield of multiplex panel testing compared with expert opinion and validated prediction models.
Latest:
Dr. Gregory Riely on Potential Treatment for Patients With MET Exon 14 MutationGregory J. Riely, MD, PhD, vice chair of the Clinical Trials Office in the Department of Medicine, Memorial Sloan Kettering Cancer Center, talks about non-small cell lung cancer (NSCLC) MET exon 14 mutations and their response to drugs like cabozantinib and crizotinib.
Latest:
Dr. Gregory Randolph on Pre-Surgical Laryngeal Assessment in Patients With Thyroid CancerRandolph says pre-operative loss of voice tracks "robustly" with invasive thyroid cancer, and being aware of this issue before surgery helps surgeons better treat their patients.
Latest:
The Future of Thyroid Cancer TreatmentGregory W. Randolph, MD, director, General and Thyroid Surgical Services, Massachusetts General Hospital, discusses the future of thyroid cancer treatment.
Latest:
Identification of Actionable Mutations Remains an Unmet Need in CRCGulam A. Manji, MD, PhD, discusses the need to identify mutations that may be actionable in patients with colorectal cancer. The identification of such mutations can further impact patient survival and improve efficacy, says Manji, in both CRC and other gastrointestinal cancers.
Latest:
The Optimal Duration of Pertuzumab Treatment for Patients With HER2+ Breast CancerGunter von Minckwitz, MD, PhD, president of the German Breast Group in Neu-Isenburg, Germany, discusses questions still surrounding the optimal duration of pertuzumab (Perjeta) treatment for patients with HER2-positive breast cancer.
Latest:
Effects of SIRT and Bevacizumab on Extrahepatic CRC MetastasesGuy Van Hazel, MD, Medical Oncologist, Mount Hospital and School of Medicine University of Western Australia, discusses the effects of selective internal radiation therapy (SIRT) and bevacizumab on extrahepatic colorectal cancer (CRC) metastases.
Latest:
Choosing Between Atezolizumab and Pembrolizumab in Lung CancerH. Jack West, MD, thoracic oncologist at the Swedish Cancer Institute of Swedish Medical Center, discusses the data with atezolizumab (Tecentriq) and pembrolizumab (Keytruda) in non-small cell lung cancer (NSCLC). West says that the choice of treatment is likely best left to the judgement of the physician and patient.
Latest:
The Impact of Breast Cancer Diagnosis on Sexual DysfunctionHadeel Assad, MD, hematology/oncology fellow, Providence Hospital and Medical Center, discusses an analysis of the impact of breast cancer diagnosis on sexual dysfunction.
Latest:
Treatment Failure in CML: Distinguishing Between Disease Resistance and Treatment IntolerancePatients with chronic myeloid leukemia can have a near-normal life expectation when treated with BCR::ABL1 tyrosine kinase inhibitors.
Latest:
RICTOR Amplification in Lung Cancer PatientsHaiying Cheng, MD, medical oncologist, Montefiore Einstein Center for Cancer Car, assistant professor, Department of Medicine (Oncology), Albert Einstein College of Medicine, discuses RICTOR amplification in patients with lung cancer.
Latest:
Survival Differences in KRAS/BRAF Mutations in mCRCHalfdan Sorbye, MD, professor, Department of Oncology and Medical Physics, Haukeland University Hospital, University of Bergen, discusses the survival differences in KRAS/BRAF mutations in patients with metastatic colorectal cancer (mCRC).
Latest:
Identifying BRCA Carriers for Better Breast Cancer Diagnosis and TreatmentHalle Moore, MD, discusses key takeaways from a study on young patients with breast cancer carrying BRCA mutations presented at the 2024 ASCO Annual Meeting.
Latest:
Expert Offers Advice to Community Oncologists for Patients With Pancreatic CancerHani M. Babiker, MD, shares his advice for community oncologists treating patients with pancreatic cancer.
